The University of Houston in partnership with Humana is now offering a six-course, fully online program focusing on value-based care. Photo via UH.edu

Last week, the University of Houston announced a new online program that will provide specialized value-based care training for providers, academia and other business and industry professionals.

UH teamed up with Kentucky-based health insurance giant, Humana, to create the new Value-based Care Specialization program that will teach the fundamentals and real-world application of value-based care. The flexible, fully-online program is being provided via the collaborative Humana Integrated Health System Sciences Institute and through global online learning platform Coursera.

"This readily available and affordable option will support those who are working with practices and providers to create better outcomes for their patients," says Tray Cockerell, director of strategy advancement for Humana, in a news release. "It's more important than ever, with the tumult caused by COVID-19, that practices focus on prevention and care coordination.

"We learned in 2020 that providers in value-based care agreements were better positioned to withstand the financial impact the pandemic brought on the health care industry because they had established patient-centered medical practices.," he continues. "Because they could quickly pivot their resources into action to best serve patients, their income was not as drastically affected as those of their fee-for-service peers."

Recent surveys have shown that there is a varied understanding of the definition of value-based care within the health care industry, and now more than ever there is a need to retool the workforce.

"It's essential that those who work to improve the health of their communities speak the same language," says Dr. LeChauncy Woodard, general internist and founding director, Humana Integrated Health System Sciences Institute at the University of Houston, in the release. "The collaboration on this content assures that everyone, from the physician and nurse, to social workers, pharmacists and claims representatives, as well as consumers of health care understand what it takes to work together. These multisector partnerships help to ensure patients are receiving the best possible care and achieving the best outcomes at the lowest possible cost."

The program consists of six courses and a capstone project, and each course features a few learning modules and a summative assignment. Participants can take any of the six courses independently — receiving a certificate for each — or collectively for the specialization designation, per the release.

"The health care industry is rapidly changing, and high-quality, flexible learning can help support medical professionals preparing for the future," says Betty Vandenbosch, chief content officer at Coursera, in the release. "We are excited to partner with leaders such as the University of Houston and Humana to offer job-relevant content in the emerging area of value-based care."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.